Infectious DiseasesHPV vaccineimmunobridging
Single-dose Cervarix induces durable seropositivity but fails HPV‑16 GMC non-inferiority versus three-dose Gardasil-4: implications from the PRIMAVERA immunobridging trial
By MedXY|Nov 24, 2025
PRIMAVERA immunobridging shows single-dose Cervarix induces near-universal seropositivity at 36 months and non-inferior HPV-18 antibodies versus three-dose Gardasil-4, but HPV-16 antibody GMCs were lower; results inform but do not yet suppo
